TippingPoint Biosciences

Cambridge, United States· Est. 2018

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $4.5M

Overview

TippingPoint Biosciences is a private, pre-clinical stage biotech developing first-in-class therapeutics targeting aberrant chromatin networks, a root cause of many cancers and genetic diseases. The company's proprietary platform aims to drug previously 'undruggable' unstructured protein interfaces unique to disease states, potentially offering greater specificity and reduced toxicity compared to existing chromatin-targeting approaches. Backed by mission-aligned investors like the Pediatric Brain Tumor Foundation and the American Cancer Society's BrightEdge, TippingPoint is advancing its lead program for pediatric brain tumors while building a pipeline for other chromatin dysfunction diseases. The company combines deep academic expertise in chromatin biology from UCSF with seasoned drug discovery and development leadership from the biopharma industry.

OncologyRare DiseasesNeurology

Technology Platform

A drug discovery platform targeting unstructured regions (IDRs) of chromatin proteins by exploiting unique inter-molecular interfaces found only in disease-driving chromatin states. Aims to increase specificity, reduce toxicity, and overcome resistance compared to traditional chromatin-targeting approaches.

Funding History

Total raised:$4.5M

Seed$4.5MUndisclosedJun 15, 2022

Opportunities

Success in pediatric DMG provides a powerful proof-of-concept for a platform applicable to a wide range of cancers and genetic diseases driven by chromatin dysfunction.

The novel mechanism targeting disordered protein interfaces could address significant limitations of current epigenetic therapies, capturing value in a large and growing market.

Strong backing from mission-driven foundations provides patient-centric credibility and access to specialized networks.

Risk Factors

High technical risk in drugging unstructured protein regions, an unproven approach with no guarantee of yielding viable drug candidates.

Heavy pipeline concentration on a single, ultra-rare pediatric cancer program creates significant vulnerability to clinical or preclinical setbacks.

Faces competition from other novel modalities (e.g., PROTACs, molecular glues) also targeting challenging chromatin factors.

Competitive Landscape

Operates in the competitive epigenetics and oncology space, competing with companies developing BET inhibitors, EZH2 inhibitors, HDAC inhibitors, and newer modalities like protein degraders. Differentiation lies in the novel target class (IDRs) and the potential for greater disease-state specificity. Key competitors include large pharma with epigenetics franchises and biotechs like Epizyme (acquired by Ipsen), Foghorn Therapeutics, and Syros Pharmaceuticals.